Taken together, effective galectin-3 inhibitors would probably need to act both intracellularly to inhibit cell-intrinsic galectin-3 as well as inactivate the abundant galectin-3 produced by stromal cells in the tumor microenvironment. This evidence concerns the gene LGALS3 and neoplasm.